Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673338 | 0.98 | EPHX1 (0.44) | GNAI3GNAO1GNAI1EPHX1SOS1 | |
| SCHEMBL27804953 | 0.95 | GNAI3 (0.41) | GNAI3GNAO1GNAI1EPHX1SOS1 | |
| SCHEMBL1009313 | 0.91 | GNAI3 (0.44) | GNAI3GNAO1GNAI1EPHX1SOS1 | |
| SCHEMBL5868698 | 0.91 | KDM1A (0.44) | GNAI3GNAO1GNAI1EPHX1SOS1 | |
| SCHEMBL13838034 | 0.89 | RAD52 (0.47) | GNAI3GNAO1GNAI1EPHX1DPP7 | |
| Hydrochloric Acid SCHEMBL4796821 | 0.88 | GNAI3 (0.47) | GNAI3GNAO1GNAI1EPHX1SOS1 | |
| SCHEMBL19366459 | 0.86 | KDM1A (0.44) | GNAI3GNAO1GNAI1EPHX1KCNH2 | |
| SCHEMBL3812253 | 0.85 | KCNH2 (0.53) | EPHX1DPP7RAD52KCNH2KDM1A | |
| SCHEMBL1678793 | 0.83 | ADH1B (0.42) | EPHX1CHRM2CHRM4CHRM5ADRA2B | |
| SCHEMBL5201541 | 0.83 | EPHX1 (0.45) | EPHX1DPP7CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103396399-B | Nitrogenated aromatic 6-membered ring derivative, and pharmaceutical agent comprising same | DAIICHI SANKYO CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-103396399-A | Nitrogenated aromatic 6-membered ring derivative, and pharmaceutical agent comprising same | ASUBIO PHARMA CO LTD | 2013-11-20 | — | — | CN | disclosed |
| CN-101730691-A | Nitrogen-containing aromatic six-membered ring derivatives and drugs containing the same | ASUBIO PHARMA CO LTD | 2010-06-09 | — | — | CN | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| EP-1558600-B1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
| CN-1708493-A | Selected CGRP antagonists, method for production and use thereof as medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-12-14 | — | — | CN | disclosed |
| EP-1558600-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004037810-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | GNAI3 472/4885GNAO1 290/4885GNAI1 451/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | GNAI3 472/4885GNAO1 290/4885GNAI1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.